{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:52Z","timestamp":1792712452435,"version":"4.5.0"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to describe baseline drug resistance in patients newly diagnosed with HIV in Brighton over a 12\u2010year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>As part of a quality improvement project, clinic data were collected for all patients newly diagnosed with HIV between January 2014 and December 2025. Locally, baseline genotypic resistance testing is routinely performed at diagnosis and assessed for resistance to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), non\u2010nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). Since 2022, baseline resistance for integrase inhibitors (INIs) has also been performed. Transmitted drug resistance mutations for NRTIs, NNRTIs and PIs were defined according to the World Health Organization (WHO) criteria. Integrase resistance mutations were identified using the Stanford HIV Drug Resistance Database. Extracted data included patient demographics, date of HIV diagnosis, HIV subtype and previous HIV pre\u2010exposure prophylaxis (HIV\u2010PrEP) use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three hundred and eighteen individuals newly diagnosed with HIV throughout the study period, of which 312 had a resistance report available for analysis. Overall, baseline drug resistance was found in 38\/312 (12%, 95% CI 8.76\u201316.33). The median age was 37\u2009years (IQR 30\u201346). 13 (39%) patients were non\u2010UK born and 17 (52%) had a non\u2010B subtype. There were 12 (4%) individuals with NRTI resistance mutations, 13 (4%) with NNRTI mutations and 5 (2%) with PI mutations. Integrase resistance mutations were found in 8\/73 (11%) between 2022 and 2025, 3 of whom had no other class resistance. Baseline drug resistance was associated with non\u2010clade B genotypes (OR\u2009=\u20092.79, 95%CI\u2009=\u20091.34\u20135.79,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) and previous HIV\u2010PrEP use (OR\u2009=\u20094.14, 95%CI\u2009=\u20091.66\u201310.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This manuscript identified a number of cases where baseline integrase resistance was identified. These data suggest that more work is needed to establish whether baseline integrase inhibitor resistance testing is warranted in all individuals newly diagnosed with HIV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70334","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:19:43Z","timestamp":1792711183000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline\n                    <scp>HIV<\/scp>\n                    genotypic resistance testing in patients newly diagnosed with\n                    <scp>HIV<\/scp>\n                    : When do we need to consider baseline integrase resistance testing for everyone?"],"prefix":"10.1111","author":[{"given":"Inessa","family":"Alekseeva","sequence":"first","affiliation":[{"name":"Brighton &amp; Sussex Medical School  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Woods","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7639-0821","authenticated-orcid":false,"given":"Amber","family":"Savary\u2010Trathen","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-0823","authenticated-orcid":false,"given":"Claire","family":"Norcross","sequence":"additional","affiliation":[{"name":"Brighton &amp; Sussex Medical School  Brighton UK"},{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"},{"name":"MRC\/UVRI\u2010LSHTM Uganda Research Unit  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-6307","authenticated-orcid":false,"given":"Daniel","family":"Richardson","sequence":"additional","affiliation":[{"name":"Brighton &amp; Sussex Medical School  Brighton UK"},{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-5860","authenticated-orcid":false,"given":"Colin","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Brighton &amp; Sussex Medical School  Brighton UK"},{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Organization WH.HIV and AIDS.2025.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance."},{"key":"e_1_2_10_3_1","unstructured":"GOV.UK.HIV testing PrEP new HIV diagnoses and care outcomes for people accessing HIV services: 2025 report GOV.UK.2025.https:\/\/www.gov.uk\/government\/statistics\/hiv-annual-data\/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2025-report."},{"issue":"5","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/hiv.13038","article-title":"Transmitted HIV\u20101 drug resistance in a large international cohort using next\u2010generation sequencing: results from the strategic timing of antiretroviral treatment (START) study","volume":"22","author":"Baxter J","year":"2021","journal-title":"HIV Med"},{"key":"e_1_2_10_5_1","volume-title":"HIV Drug Resistance: Brief Report 2024","author":"Organization WH","year":"2024"},{"issue":"3","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV\u20101 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin A","year":"2017","journal-title":"HIV Med"},{"issue":"5","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.13446","article-title":"BHIVA guidelines on antiretroviral treatment for adults living with HIV\u20101 2022","volume":"23","author":"Waters L","year":"2022","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/COH.0000000000000746","article-title":"How could HIV\u20101 drug resistance impact preexposure prophylaxis for HIV prevention?","volume":"17","author":"Parikh UM","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"e_1_2_10_9_1","unstructured":"GOV.UK.Annual epidemiological spotlight on HIV in the South East: 2022 data UK.2024.https:\/\/www.gov.uk\/government\/publications\/hiv\u2010south\u2010east\u2010annual\u2010data\u2010spotlight\/annual\u2010epidemiological\u2010spotlight\u2010on\u2010hiv\u2010in\u2010the\u2010south\u2010east\u20102022\u2010data."},{"issue":"2","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0956462420953043","article-title":"HIV\u20101 transmitted drug resistance in Brighton, UK, from 2014 to 2020","volume":"32","author":"Richardson D","year":"2021","journal-title":"Int J STD AIDS"},{"issue":"3","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV\u20101 drug\u2010resistance: 2009 update","volume":"4","author":"Bennett DE","year":"2009","journal-title":"PLoS One"},{"key":"e_1_2_10_12_1","unstructured":"Stanford.University.Stanford University HIV drug resistance database: INSTI resistance mutation scores.2026.https:\/\/hivdb.stanford.edu\/dr-summary\/mut-scores\/INSTI\/."},{"issue":"19","key":"e_1_2_10_13_1","article-title":"Piloting a surveillance system for HIV drug resistance in the European Union","volume":"24","author":"Laar MJ","year":"2019","journal-title":"Euro Surveill"},{"issue":"1","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)\u2010resistance mutations for the surveillance of transmitted HIV\u20101 drug resistance","volume":"75","author":"Tzou PL","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/dkw404","article-title":"Enhanced surveillance of HIV\u20101 drug resistance in recently infected MSM in the UK","volume":"72","author":"Cunningham E","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/hiv.70043","article-title":"Driving progress towards PrEP equity: key changes in the 2025 BASHH\/BHIVA UK PrEP guidelines","volume":"26","author":"Clutterbuck D","year":"2025","journal-title":"HIV Med"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:19:51Z","timestamp":1792711191000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":15,"alternative-id":["10.1111\/hiv.70334"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70334","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"2026-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hiv.70334"}}